Gretchen Michaelson, APRN
Adult Health · South Windsor, CTNPI 1508898800
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $146,442 of the $168,862 with a category attached, or 86.7%. AbbVie accounts for 72.6% of it on its own, with 20 other manufacturers making up the rest. Among adult health clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 904 payments — averaging $186.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$123K
- Teva Pharmaceuticals USA, Inc.$10K
- Axsome Therapeutics, Inc.$10K
- Biohaven Pharmaceutical Holding Company Ltd.$9K
- Biohaven Pharmaceuticals, Inc.$9K
- Pfizer$2K
- plus $6K from 15 others
What the payments were for
- Consulting fees$1,7351%
- Speaking & faculty fees$146,44287%
- Travel & lodging$4,5103%
- Food & beverage$16,05710%
- Education$1180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 474 | $122,669 |
| Teva Pharmaceuticals USA, Inc. | 92 | $10,217 |
| Axsome Therapeutics, Inc. | 19 | $10,194 |
| Biohaven Pharmaceutical Holding Company Ltd. | 46 | $8,950 |
| Biohaven Pharmaceuticals, Inc. | 24 | $8,577 |
| Pfizer | 94 | $2,268 |
| Lundbeck LLC | 23 | $1,661 |
| Tonix Medicines, Inc. | 7 | $1,246 |
| Biodelivery Sciences International, Inc. | 1 | $750 |
| Amgen | 29 | $488 |
| Lilly USA, LLC | 20 | $402 |
| Impel Pharmaceuticals Inc. | 11 | $276 |
| Currax Pharmaceuticals LLC | 16 | $212 |
| Scilex Pharmaceuticals Inc. | 8 | $191 |
| Upsher-smith Laboratories LLC | 8 | $175 |
| Arbor Pharmaceuticals, Inc. | 8 | $159 |
| Collegium Pharmaceutical, Inc. | 9 | $137 |
| Almatica Pharma LLC | 6 | $120 |
| Azurity Pharmaceuticals, Inc. | 5 | $102 |
| Supernus Pharmaceuticals, Inc. | 2 | $39 |
| Amneal Pharmaceuticals LLC | 2 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$99,582
- QULIPTA$47,989
- NURTEC ODT$18,206
- Symbravo$9,915
- AJOVY$9,059
- VYEPTI$1,196
- ZEMBRACE SYMTOUCH$1,139
- TOSYMRA$1,139
- ELYXYB - CELECOXIB$750
- AIMOVIG$143
How this compares
$168,862 in reported general payments places this provider in the 95th percentile of 418 adult health providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 74 | $113,882 |
| BotoxOnabotulinumtoxina | 79 | $100,317 |
| UbrelvyUbrogepant | 71 | $95,231 |
| Emgality PenGalcanezumab-Gnlm | 93 | $65,082 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 47 | $61,321 |
| QuliptaAtogepant | 22 | $30,854 |
| Ajovy SyringeFremanezumab-Vfrm | 17 | $18,035 |
| Sumatriptan Succinate | 72 | $2,820 |
| Gabapentin | 122 | $1,886 |
| RizatriptanRizatriptan Benzoate | 92 | $1,077 |
| Baclofen | 17 | $615 |
| Nortriptyline Hcl | 16 | $356 |
| Pregabalin | 11 | $239 |
| Topiramate | 32 | $177 |
| Prednisone | 21 | $131 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieBotox, Ubrelvy, Qulipta | $122,669 | $226,402172 claims |
| PfizerNurtec Odt | $2,268 | $113,88274 claims |
| Upsher-smith Laboratories LLCTopiramate | $175 | $17732 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 418 adult health providers in Connecticut.
Other adult health in South Windsor
- Mallory MerrillSouth Windsor$4K
- Leah EhleManchester$418K
- Laura MulkaWethersfield$306K
- Kimberly RyanWethersfield$74K
- Kathryn JackMeriden$67K
- Lynn RapsilberTorrington$52K
- Genice NelsonFarmington$36K
- Andrea LauterNew London$32K
- Megan CarlucciManchester$28K
- Kellie HaleNew Haven$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.